SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Coca-Cola Co. engages in the manufacturing and marketing of non-alcoholic beverages. It operates through the following segments: Europe, Middle East and Africa, Latin America, North America, Asia Pacific, Global Ventures, and Bottling Investments. The company was founded by Asa Griggs Candler on May 8, 1886 and is headquartered in Atlanta, GA.

Coca-Cola Co

Coca-Cola is trending as investors rotate into defensive staples to hedge against market volatility, driving the stock to fresh 52-week highs while analysts closely monitor upcoming earnings for signs of sustained pricing power. The community remains divided between long-term holders praising the company's dividend reliability and bears who argue the stock is currently overbought and susceptible to a significant retracement.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph is currently attracting intense community debate as investors speculate on its potential for enterprise-grade utility amid shifting regulatory discussions. While some traders are aggressively accumulating tokens in anticipation of future institutional adoption and technical catalysts, others express frustration over stagnant price action and supply dilution, reflecting a divide between long-term holders and skeptics.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is facing heightened community debate as investors weigh the impact of shifting focus toward newer market narratives against its long-term potential as a legacy meme coin. Sentiment remains deeply polarized, with active discussions focused on whether the asset is currently at a critical support level or if a broader shift in market interest is signaling a permanent decline.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is seeing intense community scrutiny ahead of the annual meeting, with shareholders actively debating whether to support the current board's compensation and dilution proposals or align with activist pressure for tighter cost controls and share repurchases. Investors remain fixated on the silence surrounding the company's proprietary flu-COVID combination vaccine and are speculating on the timing of potential partnership news or clinical developments to drive value.

Aave is a decentralized money market protocol where users can lend and borrow cryptocurrency across 20 different assets as collateral. The protocol has a native token called AAVE, which is also a governance token that lets the community decide the direction of the protocol in a collective manner. Lenders can&nbsp;earn interest by providing liquidity to the market, while borrowers can borrow by collateralizing their cryptoassets to take out loans from the liquidity pools.

AAVE

AAVE is drawing significant community attention as investors debate its role as a leading DeFi protocol, with ongoing discussions centered on its upcoming V4 upgrade and its long-term potential compared to rivals like Compound. Market participants are actively tracking price action, analyzing institutional adoption, and speculating on the impact of governance-led token buybacks on its valuation.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors monitor a critical court hearing regarding the company's efforts to regain full commercial rights for its Duchenne muscular dystrophy therapy, deramiocel. The community is focused on the potential for an injunction to resolve distribution disputes ahead of the PDUFA date, while also highlighting the FDA's recent shift toward reviewing rare disease data more favorably.

Nasdaq, Inc. is a holding company, which engages in trading, clearing, exchange technology, regulatory, securities listing, information, and public and private company services. It operates through the following segments: Capital Access Platforms, Financial Technology, and Market Services. The Capital Access Platforms segment delivers liquidity, transparency, and integrity to the corporate issuer and investment community by empowering clients to effectively navigate the capital markets, achieve their sustainability goals, and drive governance excellence. The Financial Technology segment offers platforms that improve the liquidity, transparency, and integrity of the global economy by architecting and operating the markets. The Market Services segment includes equity derivative trading and clearing, cash equity trading, fixed income, currency, and commodities trading. The company was founded by Gordon S. Macklin in 1971 and is headquartered in New York, NY.

Nasdaq Inc - Ordinary Shares - 144A

Nasdaq Inc

Nasdaq Inc. is trending as investors react to potential shifts in market structure, including proposed changes to exchange fee models, the ongoing integration of tokenized assets, and broad institutional repricing of AI-driven workflow efficiency. The community is actively debating the implications of these technological shifts alongside geopolitical tensions that are fueling volatility and intense scrutiny of market manipulation.

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as investors weigh persistent legal uncertainty surrounding Medicare reimbursement for XPHOZAH against the company's strong IBSRELA revenue momentum. While the community is actively debating the potential for an M&A catalyst, the primary focus remains on upcoming quarterly performance and the impact of the pending appellate court ruling on long-term growth guidance.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

Rocket Companies Inc

Rocket Companies is trending as investors weigh its potential as an AI-powered housing platform against ongoing macro pressures from elevated interest rates and treasury yields. The community is actively debating whether the stock's recent price volatility signals a buying opportunity or a deeper correction, with many participants focused on the company's long-term business transformation and its ability to capitalize on future rate normalization.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio Inc. (IBRX) is experiencing significant trading volume and social media chatter as retail investors weigh speculation regarding potential Russell 1000 index inclusion against ongoing community debates about short interest and the company's long-term product pipeline. Traders are closely monitoring the stock's volatility and institutional activity, with many focused on upcoming catalyst announcements rather than index rebalancing effects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Build America Boom Begins: Construction Stocks Surge as Housing Bill Triggers Sector Repricing Frenzy

Washington’s push for a sweeping housing affordability overhaul has injected fresh momentum into the residential construction complex, igniting speculation across homebuilders, building materials suppliers, and alternative construction innovators. With affordability pressures still elevated nationwide, investors are rotating into names tied to faster build cycles, lower-cost materials, and scaled production capacity, creating a broad “everything housing” bid across equities. $XERI, $KBH, $BLDR, $DFH, $CCS

Builders FirstSource (BLDR) Suffers a Larger Drop Than the General Market: Key Insights

Builders FirstSource (BLDR) reached $77.33 at the closing of the latest trading day, reflecting a -4.05% change compared to its last close.

Here is What to Know Beyond Why Builders FirstSource, Inc. (BLDR) is a Trending Stock

Recently, Zacks.com users have been paying close attention to Builders FirstSource (BLDR). This makes it worthwhile to examine what the stock has in store.

Builders FirstSource (BLDR) Stock Sinks As Market Gains: Here's Why

In the most recent trading session, Builders FirstSource (BLDR) closed at $77.77, indicating a -1.02% shift from the previous trading day.

Five Below and Builders FirstSource have been highlighted as Zacks Bull and Bear of the Day

Five Below raised FY26 guidance after strong sales and earnings growth, while Builders FirstSource faces pressure from weak demand and margin strain.

Bear of the Day: Builders FirstSource (BLDR)

Quarterly results have largely skewed sentiment around BLDR, with the company falling short of the Zacks Consensus EPS estimate by double-digit percentages in back-to-back releases. 

$500 Million Inferno Reveals Critical Problems Hidden in Plain Sight

The recent destruction of a Kimberly-Clark (NASDAQ:KMB) warehouse in Ontario, California, an event that prosecutors estimate caused roughly $500 million in damages, has generated headlines primarily because of the shocking allegations surrounding the fire. Yet beyond the criminal case itself, the incident highlights several larger issues that are increasingly affecting businesses, communities, insurers, builders, and policymakers across the United States. $XERI, $BLDR, $OC, $LPX, $JHX, $TREX

Is Trending Stock Builders FirstSource, Inc. (BLDR) a Buy Now?

Zacks.com users have recently been watching Builders FirstSource (BLDR) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Is Builders FirstSource, Inc. (BLDR) A Good Stock To Buy Now?

Is Builders FirstSource, Inc. (BLDR) A Good Stock To Buy Now...

Builders FirstSource (BLDR) Stock Moves -1.79%: What You Should Know

The latest trading day saw Builders FirstSource (BLDR) settling at $73.64, representing a -1.79% change from its previous close.

Builders FirstSource, Inc. engages in the supply and manufacture of building materials, manufactured components, and construction services to professional homebuilders, sub-contractors, remodelers, and consumers. Its products include factory-built roof and floor trusses, wall panels and stairs, vinyl windows, custom millwork and trim, and engineered wood. The company was founded by Kevin P. O'Meara, Donald F. McAleenan and John D. Roach in March 1998 and is headquartered in Irving, TX.

Builders Firstsource Inc

QXO Stock Trims Losses Overnight: Wall Street Sees TopBuild Deal Driving $50B Annual Revenue, Picks Next Potential Target

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$1.28	--	--	N/A
Q1 '26	$0.38	$0.27	-29.49%	MISSED
Q4 '25	$1.25	$1.12	-10.66%	MISSED
Q3 '25	$1.57	$1.88	19.51%	BEAT
Q2 '25	$2.26	$2.38	5.37%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

BLDRBuilders Firstsource Inc

Upcoming Earnings: Q2 '26

Historical Earnings

Latest BLDR News